RxDoctor Payments Data

Kerstin Zoschg, OD

Optometrist · Newark, NYNPI 1225699242

Payments from drug & device makers

$1,748in general payments, 2019–2025

Across 49 payments — averaging $35.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$388
  • Amgen$279
  • Bausch & Lomb Americas Inc.$268
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$147
  • Regeneron Healthcare Solutions, Inc.$135
  • Sun Pharmaceutical Industries Inc.$132
  • plus $400 from 9 others

What the payments were for

  • Food & beverage$1,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,748 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$57,236
Medicare patients
364
Services billed
636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost77$35,158
XiidraLifitegrast21$18,923
Cyclosporine31$18,745
RestasisCyclosporine11$8,990
Loteprednol Etabonate37$7,672
TyrvayaVarenicline Tartrate11$6,982
Prednisolone Acetate156$6,378
Latanoprost568$5,947
Travoprost22$4,365
RhopressaNetarsudil Mesylate13$3,918
SimbrinzaBrinzolamide/Brimonidine Tart16$3,797
Alphagan PBrimonidine Tartrate12$3,743
Fluorometholone42$3,582
Timolol Maleate214$2,936
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$2,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$21$47,892100 claims
Bausch & Lomb Americas Inc.Xiidra$268$18,92321 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$147$7,67237 claims
Oyster Point Pharma, Inc.Tyrvaya$14$6,98211 claims
AlconSimbrinza$388$3,79716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,743 optometrist providers in New York.

Other optometrist in Newark

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →